Hydrogène de France Announces the World's First Plant for Mass Production of High-Powered Fuel Cells (Over 1 MW)
10.12.2019 23:00:00 EET | Business Wire | Press release
Hydrogène de France (HDF) becomes a French industrial company by launching its high-powered fuel cell production plant in Bordeaux. This plant, with an annual production capacity of 50 MW, will be the first in the world to mass produce high-powered PACs (greater than 1 MW) using PEM (Proton Exchange Membrane) technology. The industrialization and standardization of these systems reduces their cost and improves significantly their reliability and maintenance.
This plant will produce under the brand name "HDF Industry". It will integrate the Fuel Cell stacks of Canadian company Ballard, which today has the most widely deployed technology in the world. This exclusive worldwide agreement allows HDF to offer high-powered FCs whose performance and prices are adapted to the energy market.
A worldwide ambition
HDF intends to play a pioneering role in the emerging hydrogen market. Hydrogen, considered by both industrialists and governments as one of the solutions for the energy transition, is developing in multiple directions, including mobility as well as stationary applications.
HDF's vision is based on the development of hydrogen as a fuel and a vehicle for storing electricity. Renewable energies have conquered a place in the world of energy by overcoming the challenge of competitiveness. HDF believes that the time has come to take on the next challenge, that of intermittency.
An industrial reality
HDF started its industrial program 3 years ago consulting the world's leading fuel cell companies. Ballard was selected as being the ideal partner, as they have demonstrated their experience, industrial capacity and stack lifetime. HDF's industrial plan has been developed with the ClearGen and CEOG projects and with the expertise of its employees.
The HDF Industry plant will have a production capacity of 50MW of Fuel Cell per year within 5 years.
Benefiting from Ballard's know-how and HDF's unique experience in industrial hydrogen projects, this French multimegawatt fuel cell plant has a sizeable lead in the market.
Damien Havard, President and Founder of HDF:
We are particularly pleased with this cooperation with Ballard. HDF industrializes reliable FCs at a price adapted to the market. The standardization of this strategic brick will allow the production of non-polluting and competitive electricity on a large scale. HDF provides the industrial solution that was missing to develop the massive storage of renewable energy. Our market is huge: this is the end of the intermittency of renewable energies!
About Hydrogène de France: industrialist and developer of Renewstable® power plants
A specialist in hydrogen technologies, HDF develops, finances, builds and operates multimegawatt industrial power generation infrastructures.
A pioneer in its sector of activity, HDF achieved a world first in 2019 in Martinique, the ClearGen project: the installation and commissioning of a high-powered fuel cell (1 MW), using the hydrogen co-produced by the SARA refinery by transforming it into electricity. This project is funded by Europe (FCH-JU) and SARA.
HDF marketed the Renewstable® power plants, which capture intermittent renewable energy and store it massively in the form of hydrogen to produce stable, 24-hour electricity that can be controlled like a thermal power plant at a competitive price. The first Renewstable® power plant is developed in French Guiana, in collaboration with the French infrastructure fund Meridiam and SARA: the CEOG power plant is the largest in the world storing massively renewable energy via hydrogen, to produce stable and non-polluting electricity day and night for 10,000 households. CEOG will start its construction site in early 2020 and produce its first electrons in early 2022.
As an international player, HDF Energy currently has around ten Renewstable® projects in the advanced development phase in several countries.
- HDF Energy website: www.hdf-energy.com
- HDF Industry website: www.hdf-industry.com
- CEOG Power Plant Website: www.ceog.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005394/en/
Contact information
Investor and press relations:
- HDF: communication@hdf-energy.com / +33 (0)5 56 77 77 11 11
Agence 914
Salomé EON :
salome@agence914.fr
+33 6 78 86 66 48
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom